<DOC>
	<DOCNO>NCT00811733</DOCNO>
	<brief_summary>Given tolerability efficacy ofatumumab follicular lymphoma Chronic Lymphocytic Leukemia , need improve therapy patient WM utilize non-myelosuppressive agent phase II trial ofatumumab initiate patient Waldenstrom 's Macroglobulinemia ( WM ) .</brief_summary>
	<brief_title>A Phase II Trial Ofatumumab Subjects With Waldenstrom 's Macroglobulinemia</brief_title>
	<detailed_description />
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Confirmed active Waldenstrom 's Macroglobulinemia require treatment . Ambulatory capable selfcare . Up 50 % waking hour . Adequate organ function . Detectable CD20 positive tumor cell . Measurable disease define monoclonal IgM paraprotein level great 1000 mg/dL . Treatment WM within past 28 day . Treatment rituximab alemtuzamab within past 3 month . Certain heart problem , chronic current active infection control oral antibiotic , current cancer within last 5 year . Current participation another interventional clinical study . Lactating pregnant woman female patient childbearing potential ( male patient partner ) willing use adequate contraception . Active cerebrovascular disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Waldenstrom 's Macroglobulinemia</keyword>
	<keyword>Ofatumumab</keyword>
</DOC>